Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why this Iranian island looks like Mars after it rains - 2She was moments away from giving birth. The hospital discharged her
- 3Moon rocket and weather are on NASA's side for the first astronaut launch in decades
- 4What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- 5Three killed as unfinished building collapses on church service in Ghana
- Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- Nations for Rock Climbing
- A Concise History Of The Entertainment world
- A Manual for Well known Western television Series
- Finding China: Four Urban areas for a Remarkable Excursion
- Figure out How to Augment Your Rooftop Substitution Speculation
- Is Chinese food truly flavorful?
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- 25 of the world’s best sandwiches
